Andere talen 60 Degrees Pharmaceuticals, Inc.

Aandelen

SXTP

US83006G1040

Vertraagde tijd Nasdaq Andere beurzen 21:58:37 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,256 ^USD	-4,69%		-10,92%	-75,37%

27/06	60 Degrees Pharmaceuticals, Inc. Kondigt aan dat de eerste patiënt is ingeschreven in de klinische studie van 60 Degrees Pharmaceuticals naar Tafenoquine voor Babesiosis in het Tufts Medical Center	CI
30/05	60 Degrees Pharmaceuticals, Inc. Sluit een overeenkomst met Tufts Medical Center in Boston voor het uitvoeren van het eerste klinische onderzoek naar Tafenoquine bij de behandeling van Babesiosis-patiënten bij mensen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind	27/06
60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center	27/06
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis	11/06
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	30/05
60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	30/05
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20/05
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20/05
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	15/05
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	08/05
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02/05
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02/05
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	03/04
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14/03
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14/03
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	20/02
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	08/02
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer	08/02
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering	31/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen 60 Degrees Pharmaceuticals, Inc.

Aandelen

SXTP

US83006G1040

Andere talen

Filters